FindTrial
Sign In

How Common Are Kidney Problems During Cisplatin Chemotherapy and What Increases the Risk

Incidence and risk factors of acute kidney injury associated with cisplatin-based chemotherapy a prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/110167
Enrollment
90
Registered
2026-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Intervention5: Nil: Nil

Sponsors

Kasturba Medical College Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged more than or equal to 18 years Histologically confirmed solid organ malignancy Planned to receive cisplatinbased chemotherapy for the first time in the current treatment course

Exclusion criteria

Exclusion criteria: Patients on maintenance dialysis before initiation of cisplatin Previous exposure to cisplatin within the past 12 months Pregnant or lactating women Inability or unwillingness to comply with protocol-mandated follow up

Design outcomes

Primary

MeasureTime frame
To determine the incidence and severity of acute kidney injury in adults receiving cisplatin-based chemotherapy for solid organ malignanciesTimepoint: 6 months from recruitment—

Secondary

MeasureTime frame
To identify clinical, biochemical, and treatment-related factors independently associated with the development of acute kidney injury following cisplatin-based chemotherapy. Timepoint: 6 months from recruitment;To evaluate changes in renal function, measured by estimated glomerular filtration rate (eGFR), from baseline to 6 months following initiation of cisplatin therapy. Timepoint: 6 months from recruitment;To document short-term clinical outcomes including requirement for renal replacement therapy (RRT), unplanned hospitalisations, mortality, and chemotherapy dose modification or discontinuation within 6 months of cisplatin initiation. Timepoint: 6 months from recruitment;To compare the predictive performance of CKD-EPI, MDRD, and Cockcroft Gault equations in identifying the risk of AKI associated with cisplatin-based chemotherapy. Timepoint: 6 months from recruitment—

Countries

India

Contacts

Public ContactDr Srinivas Vinayak Shenoy

Department of Nephrology, Kasturba Hospital, Manipal.

shenoy.srinivas@manipal.edu9844374705

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026